EyePoint Pharmaceuticals, Inc. — Director's Dealing 2024

Aug 20, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2024-08-16

Reporting Person: Lurker Nancy (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-16	Common Stock	P	3173.00	$7.88	Acquired	97635.00	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	126889.00	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.87 to $7.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.